Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1462098rdf:typepubmed:Citationlld:pubmed
pubmed-article:1462098lifeskim:mentionsumls-concept:C0005684lld:lifeskim
pubmed-article:1462098lifeskim:mentionsumls-concept:C0597032lld:lifeskim
pubmed-article:1462098lifeskim:mentionsumls-concept:C0178679lld:lifeskim
pubmed-article:1462098lifeskim:mentionsumls-concept:C0431085lld:lifeskim
pubmed-article:1462098lifeskim:mentionsumls-concept:C0019409lld:lifeskim
pubmed-article:1462098lifeskim:mentionsumls-concept:C0086272lld:lifeskim
pubmed-article:1462098pubmed:issue5lld:pubmed
pubmed-article:1462098pubmed:dateCreated1993-1-14lld:pubmed
pubmed-article:1462098pubmed:abstractTextThe histogenetic relationships between the subtypes of bladder cancer are not known. Each common pattern (transitional cell carcinoma, adenocarcinoma, and squamous carcinoma) can exist independently, although they may coexist in primary or metastatic bladder cancers, and tumors that are predominantly composed of transitional cell carcinoma may have regions of squamous or glandular differentiation. Morphologically identical tumors exhibit marked variation in their natural history and response to treatment. To study these aspects of the biology of human bladder cancer, a series of cell lines have been established and characterized as xenografts and in tissue culture. These studies have shown a likely common origin for transitional cell carcinoma, adenocarcinoma, and squamous carcinoma of the bladder. Morphologically similar xenografts and cell lines in vitro have shown a broad range of functional heterogeneity, including ultrastructure, tumor marker production, ploidy, cell surface characteristics, and response to chemotherapy. These are useful models of heterogeneity of response to treatment with established and new cytotoxic agents.lld:pubmed
pubmed-article:1462098pubmed:languageenglld:pubmed
pubmed-article:1462098pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1462098pubmed:citationSubsetIMlld:pubmed
pubmed-article:1462098pubmed:statusMEDLINElld:pubmed
pubmed-article:1462098pubmed:issn8756-0437lld:pubmed
pubmed-article:1462098pubmed:authorpubmed-author:BrownJ LJLlld:pubmed
pubmed-article:1462098pubmed:authorpubmed-author:RussellP JPJlld:pubmed
pubmed-article:1462098pubmed:authorpubmed-author:RaghavanDDlld:pubmed
pubmed-article:1462098pubmed:issnTypePrintlld:pubmed
pubmed-article:1462098pubmed:volume8lld:pubmed
pubmed-article:1462098pubmed:ownerNLMlld:pubmed
pubmed-article:1462098pubmed:authorsCompleteYlld:pubmed
pubmed-article:1462098pubmed:pagination279-84lld:pubmed
pubmed-article:1462098pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1462098pubmed:meshHeadingpubmed-meshheading:1462098-...lld:pubmed
pubmed-article:1462098pubmed:meshHeadingpubmed-meshheading:1462098-...lld:pubmed
pubmed-article:1462098pubmed:meshHeadingpubmed-meshheading:1462098-...lld:pubmed
pubmed-article:1462098pubmed:meshHeadingpubmed-meshheading:1462098-...lld:pubmed
pubmed-article:1462098pubmed:meshHeadingpubmed-meshheading:1462098-...lld:pubmed
pubmed-article:1462098pubmed:meshHeadingpubmed-meshheading:1462098-...lld:pubmed
pubmed-article:1462098pubmed:meshHeadingpubmed-meshheading:1462098-...lld:pubmed
pubmed-article:1462098pubmed:meshHeadingpubmed-meshheading:1462098-...lld:pubmed
pubmed-article:1462098pubmed:meshHeadingpubmed-meshheading:1462098-...lld:pubmed
pubmed-article:1462098pubmed:meshHeadingpubmed-meshheading:1462098-...lld:pubmed
pubmed-article:1462098pubmed:articleTitleExperimental models of histogenesis and tumor cell heterogeneity in bladder cancer.lld:pubmed
pubmed-article:1462098pubmed:affiliationUrological Cancer Research Unit, Royal Prince Alfred Hospital, Sydney, NSW, Australia.lld:pubmed
pubmed-article:1462098pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1462098pubmed:publicationTypeReviewlld:pubmed
pubmed-article:1462098pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed